Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2014-07-31 Capital/Financing Update
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 100% confidence The document is a 424B4 prospectus related to an initial public offering (IPO) of ordinary shares by Bio Blast Pharma Ltd. It includes detailed information about the offering, share price, underwriting, risk factors, business overview, management, and financial data. The document is a registration statement/prospectus filed with the SEC for a public offering of shares, which is a capital raising event. This type of document is classified as a Capital/Financing Update (CAP) because it provides updates on company fundraising and financing activities. It is not an annual report, earnings release, or any other report type. The document length is substantial and contains detailed offering information, consistent with a capital raising filing.
2014-07-31 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2014-07-31 English
Regulatory Filings 2014
Regulatory Filings
2014-07-31 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from underwriters to the SEC requesting acceleration of effectiveness for a Registration Statement on Form F-1, which is related to a securities offering. It includes details about distribution of preliminary prospectuses and compliance with securities regulations. The document is short (2239 characters) and is a correspondence related to a registration statement, not the registration statement itself or a financial report. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory communication that does not fit into other specific categories like capital/financing update or prospectus filings.
2014-07-28 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Bio Blast Pharma Ltd. to the SEC requesting acceleration of the effectiveness of a Registration Statement No. 333-193824 on Form F-1. It is a formal communication related to the registration process for a securities offering, specifically under the Securities Act of 1933. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory filing related to the registration and effectiveness of a securities offering, not a report or announcement of financial results. The document length is short (2028 characters) and is a formal request letter, fitting the category of Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) which would require more detailed information about the offering or capital changes. Therefore, the best classification is Regulatory Filings (RNS).
2014-07-28 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It describes the registration of ordinary shares on NASDAQ and references a prior registration statement (Form F-1). The document is a regulatory filing related to securities registration, not a financial report, earnings release, or management information. It is a formal compliance document for securities registration purposes. Given the nature and content, it fits best under Regulatory Filings (RNS). The document length is short (3192 characters), and it is not an announcement of a report but the actual filing form itself.
2014-07-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.